|
|
News
Press Releases
All Releases
 |
Aastrom Biosciences Announces Closing of Unit Offering
01-21-10
|
11.3 KB |
|
| |
ANN ARBOR, Mich., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced the closing of its previously announced underwritten public offering from which the Company received approximately $12.4 million in net pro...
|
|
Aastrom Biosciences Announces Pricing of Unit Offering
01-15-10
|
10.8 KB |
|
| |
ANN ARBOR, Mich., Jan. 15, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced the pricing of its previously announced underwritten public offering of 46,154,000 units at a public offering price of $0.26 per unit. Each...
|
|
Aastrom Biosciences Announces Proposed Public Offering of Units
01-14-10
|
10.3 KB |
|
| |
ANN ARBOR, Mich., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that it intends to offer to sell, subject to market and other conditions, units consisting of shares of its common stock, Class A warrants ...
|
|
Aastrom Biosciences Shareholders Approve All 2009 Proxy Proposals
12-21-09
|
11.0 KB |
|
| |
ANN ARBOR, Mich., Dec. 21, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that shareholders of the Company approved all five proxy proposals at the Annual Meeting of Shareholders held December 14, 2009. Af...
|
|
NASDAQ Hearings Panel Grants Exception Period to Aastrom Based on Request to Remain Listed on the NASDAQ Stock Market
12-09-09
|
10.9 KB |
|
| |
ANN ARBOR, Mich., Dec. 9, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that the NASDAQ Hearings Panel (Panel) has granted the Company's request to remain listed on the NASDAQ Stock Market (NASDAQ) until ...
|
|
Webcast Alert: Aastrom Biosciences Announces Webcast for Annual Meeting of Shareholders
12-09-09
|
8.8 KB |
|
| |
Ann Arbor, MI, December 9, 2009 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast:
What:
Aastrom Biosciences Fiscal Year 2009 Annual Meeting of Shareholders
...
|
|
Updates and Results From Aastrom's Vascular Program Presented at an American Heart Association Satellite Symposium
11-16-09
|
13.4 KB |
|
| |
ANN ARBOR, Mich., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced that two oral presentations regarding the Company's vascular clinical program were given Sunday evening at an American Heart Association ...
|
|
Interim Results From Aastrom's IMPACT-DCM Cardiac Trial Presented at The American Heart Association Meeting
11-16-09
|
14.3 KB |
|
| |
ANN ARBOR, Mich., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that Amit N. Patel, M.D., M.S., Associate Professor of Surgery at the University of Utah School of Medicine and the National Princi...
|
|
Aastrom to Initiate Second Phase II Clinical Trial for Treatment of Severe Chronic Heart Failure
11-10-09
|
11.1 KB |
|
| |
ANN ARBOR, Mich., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that the Company will initiate its second clinical trial for the treatment of dilated cardiomyopathy (DCM), a severe disease associated wit...
|
|
Aastrom Biosciences Reports First Quarter Fiscal Year 2010 Financial Results
11-06-09
|
19.2 KB |
|
| |
ANN ARBOR, Mich., Nov. 6, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today reported financial results and operational updates for the first fiscal quarter ended September 30, 2009. Aastrom continues to operate in a capital-ef...
|
|
Harold C. Urschel, Jr., M.D. Joins Aastrom Biosciences' Board of Directors
10-20-09
|
11.4 KB |
|
| |
ANN ARBOR, Mich., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, today announced that Harold C. Urschel, Jr., M.D., has been elected to the Company's Board of Directors.
Dr. Urschel is currently Chair of Cardiovascula...
|
|
Aastrom Receives Letter From NASDAQ Regarding Continued Non-Compliance With Minimum Bid Price Rule
10-07-09
|
9.7 KB |
|
| |
ANN ARBOR, Mich., Oct. 7, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of chronic cardiovascular diseases, announced today that it received a Staff Determination letter from the NASDAQ Stock Market (NASDAQ) on October 2, 2009 indicating that the Company has not r...
|
|
Aastrom Biosciences to Present At Maxim Group Growth Conference
09-24-09
|
8.3 KB |
|
| |
ANN ARBOR, Mich., Sept. 24, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, will present at the Maxim Group Growth Conference. The conference will be he...
|
|
Update On Aastrom's Cardiovascular Programs to be Presented At Transcatheter Cardiovascular Therapeutics Annual Meeting by Amit N. Patel, M.D.
09-22-09
|
12.4 KB |
|
| |
ANN ARBOR, Mich., Sept. 22, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced today that Dr. Amit N. Patel, Associate Professor of Surgery at the University of Utah School of Medicine and National Principal Investigator...
|
|
Aastrom Biosciences Reports Fourth Quarter and Fiscal Year 2009 Financial Results
09-14-09
|
20.5 KB |
|
| |
ANN ARBOR, Mich., Sept. 14, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today reported financial results for the fourth quarter and fiscal year ended June 30, 2009. The Company also reported clinical and operational achievements since the beginning of the quarter, including:
* U...
|
|
Aastrom Announces Transitions in Senior Management
09-03-09
|
11.1 KB |
|
| |
ANN ARBOR, Mich., Sept. 3, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced an executive management transition process that will strengthen and expand the senior leadership team over the next several months. George W. ...
|
|
Compassionate Use Patients in Spain Treated With Adult Stem Cell Therapy Demonstrate Jaw Bone Regeneration Enabling Dental Implants
08-10-09
|
10.9 KB |
|
| |
ANN ARBOR, Mich., Aug. 10, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that results from compassionate use treatments using Aastrom's Bone Repair Cells (BRCs) in patients suffering from severe craniofacial defects were presented at the 2nd Annual Congress of Regenerative...
|
|
Aastrom Biosciences to Present At BMO Capital Markets Healthcare Conference
08-03-09
|
8.4 KB |
|
| |
ANN ARBOR, Mich., Aug. 3, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today announced that George Dunbar, President and Chief Executive Officer, and Elmar Burchardt, MD, PhD, Vice President, Medical Affairs, will present at...
|
|
Aastrom Biosciences Receives Notification That NASDAQ to Continue Temporary Suspension of Certain Continued Listing Requirements
07-14-09
|
8.5 KB |
|
| |
ANN ARBOR, Mich., July 14, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced that the Company received Issuer Alert #2009-004 from The Nasdaq Stock Market LLC ("NASDAQ"). The Issuer Alert states that NASDAQ is continuin...
|
|
FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial
06-18-09
|
12.0 KB |
|
| |
ANN ARBOR, Mich., June 18, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, today reported that the U.S. Food and Drug Administration (FDA) has removed the clinical hold from the Company's U.S. Phase II IMPACT-DCM clinical trial...
|
|
|
=add release to Briefcase |
Shareholder Tools
|
Print page |
Email page
